Tepezza Injection, Powder, Lyophilized, For Solution
Product Images NDC 75987-130

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Tepezza (NDC 75987-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Horizon Therapeutics Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tepezza 01)

A line graph comparing two groups, Placebo (N=42) and TEPEZZA (N=41), showing proptosis change from baseline (mm) over 24 weeks. The x-axis shows time points at baseline, week 6, 12, 18, and 24. The y-axis indicates proptosis change in millimeters from baseline. TEPEZZA group shows a progressive decrease in proptosis, reaching about -3.32 mm at week 24, while the Placebo group shows minimal change, remaining near baseline throughout the period.*

FDA Label Image

Principal Display Panel (500 mg Vial Carton)

Packaging label for TEPEZZA (teprotumumab-trbw) 500 mg/vial injection, powder lyophilized for solution, marketed by Horizon Therapeutics USA, Inc. The label specifies it is for intravenous infusion only and single-dose use. The label includes ingredients, storage instructions, and manufacturer details for this human prescription drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.